肾缺血-再灌注肺损伤发病机制及治疗  

Pathogenesis and treatment of renal ischemia-reperfusion lung injury

作　　者：张华阳(综述) 张俊勇[1] 郑白术 葛成国(审校)[1] ZHANG Huayang;ZHANG Junyong;ZHENG Baishu;GE Chengguo(Department of Urology,Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院泌尿外科,重庆400010

出　　处：《临床与病理杂志》2022年第9期2284-2291,共8页Journal of Clinical and Pathological Research

基　　金：国家自然科学基金(81803057)。

摘　　要：肾缺血-再灌注(renal ischemic-reperfusion,RIR)后会诱发急性肺损伤(acute lung injury,ALI),导致严重的低氧血症,同时也增加了缺血性肾脏病患者的死亡风险。因此,对肾缺血再灌注肺损伤(renal ischemia-reperfusion lung injury,RILI)发生机制及治疗策略的探索也逐渐受到重视。RILI损伤机制极其复杂,为多因素共同作用的结果,可显著增加患者病死率,目前临床只能采用对症支持治疗。相关治疗药物仅限于基础研究阶段,其在人体中的药物代谢动力学、疗效以及毒性尚不清楚,有待进一步与临床接轨。Acute lung injury(ALI) induced by renal ischemia-reperfusion(RIR) leads to severe hypoxemia and increases the risk of death in patients with ischemic kidney disease. Therefore, the exploration of renal ischemia-reperfusion lung injury(RILI) mechanism and relevant treatment strategy has gradually received attention. The damage mechanism of RILI is extremely complicated and influenced by multiple factors. RILI can significantly increase the mortality of the patients. Currently, only supportive treatment for symptoms can be applied clinically. Related therapeutic drugs are limited to the stage of basic research. Their pharmacokinetics, efficacy, and toxicity in human body are still unknown and need to be further integrated into clinical practice.

关 键 词：肾缺血-再灌注 肺损伤 发病机制 治疗 

分 类 号：R692[医药卫生—泌尿科学]